tradingkey.logo
tradingkey.logo
Search

ADMA Biologics Inc

ADMA
Add to Watchlist
8.610USD
+0.240+2.87%
Close 07/01, 16:00ETQuotes delayed by 15 min
2.00BMarket Cap
12.38P/E TTM

ADMA Biologics Inc

8.610
+0.240+2.87%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+2.87%

5 Days

-1.03%

1 Month

+8.99%

6 Months

-52.80%

Year to Date

-52.80%

1 Year

-51.85%

Key Figures
8.560Open
8.755High
3.04MVolume
12.38P/E TTM
7.92P/E Dynamic
--Dividend TTM
1.31%Turnover Ratio
8.370Prev. Close
8.520Low
19.13MTurnover
10.12P/E Static
5.12P/B
0.00%Div Yield TTM
28.13%ROA
22.37052wk High
0.77Volume Ratio
197.67MNet Profit
232.29MShares
0.6954EPS TTM
0.74Beta
43.30%ROE
7.21052wk Low
2.81%Amplitude
70.48%Gross Margin
2.00BMarket Cap
3.27Reward/Risk
3.09%Risk Rate

TradingKey Stock Score of ADMA Biologics Inc

Currency: USD Updated: 2026-07-01

Key Insights

ADMA Biologics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 35 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.60.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADMA Biologics Inc's Score

Industry at a Glance

Industry Ranking
35 / 157
Overall Ranking
91 / 4564
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

ADMA Biologics Inc Highlights

StrengthsRisks
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 97.58% year-on-year.
Fairly Valued
The company’s latest PE is 12.38, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 218.01M shares, decreasing 13.44% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.76M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.05.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
17.600
Target Price
+110.27%
Upside Space

ADMA Biologics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ADMA Biologics Inc Info

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
CompanyADMA Biologics Inc
CEOGrossman (Adam S)
Websitehttps://www.admabiologics.com/

FAQs

What is the current price of ADMA Biologics Inc (ADMA)?

The current price of ADMA Biologics Inc (ADMA) is 8.61.

What is the symbol of ADMA Biologics Inc?

The ticker symbol of ADMA Biologics Inc is ADMA.

What is the 52-week high of ADMA Biologics Inc?

The 52-week high of ADMA Biologics Inc is 22.37.

What is the 52-week low of ADMA Biologics Inc?

The 52-week low of ADMA Biologics Inc is 7.21.

What is the market capitalization of ADMA Biologics Inc?

The market capitalization of ADMA Biologics Inc is 2.00B.

Is ADMA Biologics Inc (ADMA) currently rated as Buy, Hold, or Sell?

According to analysts, ADMA Biologics Inc (ADMA) has an overall rating of Buy, with a price target of 17.60.

What is the Earnings Per Share (EPS TTM) of ADMA Biologics Inc (ADMA)?

The Earnings Per Share (EPS TTM) of ADMA Biologics Inc (ADMA) is 0.62.